The FDA faces scrutiny over informal expert consultation processes lacking transparency and concerns about delayed reviews, particularly impacting ultrarare disease drug approvals. Recent internal FDA town halls reveal employee worries about staff levels and procedural issues. Notably, some decisions have stirred controversy by bypassing standard advisory committee protocols. These factors contribute to ongoing debates about regulatory practices and innovation facilitation within the FDA.